News06/05/2025
Kleiner Perkins leads NewLimit Series B
Kleiner Perkins →Kleiner Perkins announced that it is leading NewLimit’s Series B and increasing its investment in the company. NewLimit develops medicines based on epigenetic reprogramming.
Kleiner Perkins announced that it is leading NewLimit’s Series B and increasing its investment in the company. NewLimit develops medicines based on epigenetic reprogramming.